Glucosamine and Cancer Incidence in Osteoarthritis: A Prevalent New‐User Cohort Design
Main finding · Any cancer incidenceResult — go to the resultHazard ratio 0.97 95% CI 0.91–1.02Authors' conclusion
In this large, real-world study of patients with osteoarthritis, designed to emulate a trial, treatment with glucosamine did not reduce the incidence of cancer.
Study context
- Population
- Patients diagnosed with OA during 1995 through 2017, UK Clinical Practice Research Datalinkmatched cohort
- Participants
- 20,541 vs 20,541
- Exposure
- Glucosamine initiators vs matched non-users
- Glucosamine initiatorsn = 20,541
- Non-usersn = 20,541reference
- Outcome
- Any cancer incidence
Methodological detailsprevalent new-user cohort design, matched on time-conditional propensity scores, designed to emulate a trial
- Prevalent new-user cohort design
- Matched on time-conditional propensity scores
- Designed to emulate a trial
Main finding
As reported in the abstract
average follow-up of eight years
Hazard ratio
0.97
95% CI 0.91–1.02
Glucosamine initiatorsvs Non-users
HR 0.97 (95% CI 0.91–1.02)
- Overall incidence rate of any cancer
- 16.4 per 1,000 per year
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Lung cancer | 0.99 (0.83–1.18) | |
| Colorectal cancer | 1.11 (0.93–1.33) | |
| Breast cancer in women | 1.07 (0.93–1.23) | |
| Prostate cancer | 1.03 (0.88–1.22) | |
| 0.512Hazard ratio (log scale) |
Original publication
Glucosamine and Cancer Incidence in Osteoarthritis: A Prevalent New‐User Cohort Design. Arthritis Care Res (Hoboken). Published 8 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →